Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kissei Pharmaceutical Co., Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are handled by 2 distinct examiners but are both located within 1 distinct art unit. This concentration in a single art unit suggests that the company's pending pharmaceutical matters are closely related in subject matter, even though they are being reviewed by different individuals.
The busiest examiner, NESTOR, DONNA MICHELLE, is responsible for 1 pending office action. Because there are 2 distinct examiners for 2 pending office actions, each examiner holds one action. While the examiners are different, the fact that they both operate within 1 distinct art unit may lead to more consistent examination standards compared to a docket spread across multiple units. Practitioners can leverage this art unit concentration to identify common themes or procedural trends that might apply to both of the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18873098 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | NESTOR, DONNA MICHELLE | — |
| 18634241 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873098 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | NESTOR, DONNA MICHELLE | 1627 | §112DP | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18634241 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | HUI, SAN MING R | 1627 | §103DP | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKissei Pharmaceutical Co., Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Donna Michelle Nestor has the most, with 1 of Kissei Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
